Equity Valuation Fresenius Medical Care AG & Co. KGaA
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.14/42488 |
Resumo: | This dissertation primarily aims to determine a target share price for Fresenius Medical Care, a Germany-based dialysis services and dialysis product provider. The company recently faced several macroeconomic headwinds, namely Covid-19, labour shortage, and inflation, lowering its profitability and thus decreasing the attractiveness for shareholders. In response, the company’s management issued a transformation program in 2020, which is expected to be completed by 2025. Main valuation methodologies applied are Discounted Cash Flows and Comparable Company Analysis, capturing the firm’s fundamental value with an infrastructure like business model, and reflecting the market perception of the industry’s prospects. Following the assumptions, the DCF reveals an intrinsic value of EUR 49.96 for the 31st of December 2022, representing an upside potential of 63% to the year-end share price of EUR 30.57. A limitation is certainly the yet-to-be-proven benefits related to the transformation program. Nevertheless, managements communicated goals appear to be realistic, given the company’s past financial track record with EBITDA margins between 19% and 22% (FY19A FY21A) and unparalleled market position. In line with the derived share price is the company’s current stock price (as of 31st of March 2023) of EUR 39.1, showcasing a 28% increase in the first quarter. Considering even the new share price, the upside potential is still 28%, leading to a strong buy recommendation. In addition, the trading level of comparable companies and conducted sensitivity analyses support this opinion. |
id |
RCAP_89d09016743ebc3208e6664652f1bb7a |
---|---|
oai_identifier_str |
oai:repositorio.ucp.pt:10400.14/42488 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Equity Valuation Fresenius Medical Care AG & Co. KGaAEquity ValuationDialysisDiscounted cash flowsAvaliação de AcçõesDiáliseFluxo de caixa descontadosDomínio/Área Científica::Ciências Sociais::Economia e GestãoThis dissertation primarily aims to determine a target share price for Fresenius Medical Care, a Germany-based dialysis services and dialysis product provider. The company recently faced several macroeconomic headwinds, namely Covid-19, labour shortage, and inflation, lowering its profitability and thus decreasing the attractiveness for shareholders. In response, the company’s management issued a transformation program in 2020, which is expected to be completed by 2025. Main valuation methodologies applied are Discounted Cash Flows and Comparable Company Analysis, capturing the firm’s fundamental value with an infrastructure like business model, and reflecting the market perception of the industry’s prospects. Following the assumptions, the DCF reveals an intrinsic value of EUR 49.96 for the 31st of December 2022, representing an upside potential of 63% to the year-end share price of EUR 30.57. A limitation is certainly the yet-to-be-proven benefits related to the transformation program. Nevertheless, managements communicated goals appear to be realistic, given the company’s past financial track record with EBITDA margins between 19% and 22% (FY19A FY21A) and unparalleled market position. In line with the derived share price is the company’s current stock price (as of 31st of March 2023) of EUR 39.1, showcasing a 28% increase in the first quarter. Considering even the new share price, the upside potential is still 28%, leading to a strong buy recommendation. In addition, the trading level of comparable companies and conducted sensitivity analyses support this opinion.Esta dissertação tem como objetivo principal determinar um preço-alvo para as ações da Fresenius Medical Care, uma empresa sediada na Alemanha que fornece serviços de diálise e produtos para diálise. Desafios recentes, como Covid-19, escassez de mão de obra e inflação, afetaram sua lucratividade e atratividade para acionistas. A administração lançou um programa de transformação em 2020, previsto para ser concluído até 2025. As principais metodologias de valoração são Fluxos de Caixa Descontados e Análise de Empresas Comparáveis, refletindo a percepção do mercado e o valor fundamental da empresa. Com base nas suposições, o Fluxo de Caixa Descontado indica um valor intrínseco de EUR 49.96 em 31 de dezembro de 2022, potencializando uma valorização de 63% em relação ao preço de EUR 30.57 no final do ano. A limitação é a falta de comprovação dos benefícios do programa de transformação. No entanto, as metas comunicadas pela administração parecem realistas, considerando o histórico financeiro da empresa, com margens de EBITDA entre 19% e 22% (FY19A-FY21A) e uma posição de mercado excepcional. O preço atual das ações em 31 de março de 2023 é EUR 39.1, um aumento de 28% no primeiro trimestre. Mesmo com o novo preço das ações, há um potencial de valorização de 28%, indicando uma forte recomendação de compra. O nível de negociação de empresas comparáveis e as análises de sensibilidade corroboram essa opinião.Martins, José Carlos TudelaVeritati - Repositório Institucional da Universidade Católica PortuguesaBeissel, Philipp Alexander2023-06-292023-062024-05-31T00:00:00Z2023-06-29T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.14/42488TID:203329015enginfo:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-09-26T01:44:03Zoai:repositorio.ucp.pt:10400.14/42488Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:30:56.497862Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Equity Valuation Fresenius Medical Care AG & Co. KGaA |
title |
Equity Valuation Fresenius Medical Care AG & Co. KGaA |
spellingShingle |
Equity Valuation Fresenius Medical Care AG & Co. KGaA Beissel, Philipp Alexander Equity Valuation Dialysis Discounted cash flows Avaliação de Acções Diálise Fluxo de caixa descontados Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
title_short |
Equity Valuation Fresenius Medical Care AG & Co. KGaA |
title_full |
Equity Valuation Fresenius Medical Care AG & Co. KGaA |
title_fullStr |
Equity Valuation Fresenius Medical Care AG & Co. KGaA |
title_full_unstemmed |
Equity Valuation Fresenius Medical Care AG & Co. KGaA |
title_sort |
Equity Valuation Fresenius Medical Care AG & Co. KGaA |
author |
Beissel, Philipp Alexander |
author_facet |
Beissel, Philipp Alexander |
author_role |
author |
dc.contributor.none.fl_str_mv |
Martins, José Carlos Tudela Veritati - Repositório Institucional da Universidade Católica Portuguesa |
dc.contributor.author.fl_str_mv |
Beissel, Philipp Alexander |
dc.subject.por.fl_str_mv |
Equity Valuation Dialysis Discounted cash flows Avaliação de Acções Diálise Fluxo de caixa descontados Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
topic |
Equity Valuation Dialysis Discounted cash flows Avaliação de Acções Diálise Fluxo de caixa descontados Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
description |
This dissertation primarily aims to determine a target share price for Fresenius Medical Care, a Germany-based dialysis services and dialysis product provider. The company recently faced several macroeconomic headwinds, namely Covid-19, labour shortage, and inflation, lowering its profitability and thus decreasing the attractiveness for shareholders. In response, the company’s management issued a transformation program in 2020, which is expected to be completed by 2025. Main valuation methodologies applied are Discounted Cash Flows and Comparable Company Analysis, capturing the firm’s fundamental value with an infrastructure like business model, and reflecting the market perception of the industry’s prospects. Following the assumptions, the DCF reveals an intrinsic value of EUR 49.96 for the 31st of December 2022, representing an upside potential of 63% to the year-end share price of EUR 30.57. A limitation is certainly the yet-to-be-proven benefits related to the transformation program. Nevertheless, managements communicated goals appear to be realistic, given the company’s past financial track record with EBITDA margins between 19% and 22% (FY19A FY21A) and unparalleled market position. In line with the derived share price is the company’s current stock price (as of 31st of March 2023) of EUR 39.1, showcasing a 28% increase in the first quarter. Considering even the new share price, the upside potential is still 28%, leading to a strong buy recommendation. In addition, the trading level of comparable companies and conducted sensitivity analyses support this opinion. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-06-29 2023-06 2023-06-29T00:00:00Z 2024-05-31T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.14/42488 TID:203329015 |
url |
http://hdl.handle.net/10400.14/42488 |
identifier_str_mv |
TID:203329015 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/embargoedAccess |
eu_rights_str_mv |
embargoedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133577635430400 |